Antibiotics and the developing intestinal microbiome, metabolome and inflammatory environment in a randomized trial of preterm infants
| Autor: | Eric W. Triplett, Timothy J. Garrett, Kelley Lobean McKinley, Jordan T. Russell, Nan Li, Catalina Bazacliu, Diomel de la Cruz, Laura Patton, J. Lauren Ruoss, Josef Neu, Richard A. Polin |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty medicine.drug_class Science Antibiotics Microbiology Article law.invention Veillonella 03 medical and health sciences Feces 0302 clinical medicine Immune system Medical research Randomized controlled trial law Pregnancy 030225 pediatrics Internal medicine RNA Ribosomal 16S medicine Metabolome Humans Metabolomics Microbiome gamma-Aminobutyric Acid Inflammation Multidisciplinary business.industry Microbiota medicine.disease Anti-Bacterial Agents Gastrointestinal Microbiome 030104 developmental biology Intestinal Microbiome Cohort Dysbiosis Medicine Female business Infant Premature Metabolic Networks and Pathways |
| Zdroj: | Scientific Reports, Vol 11, Iss 1, Pp 1-16 (2021) Scientific Reports |
| ISSN: | 2045-2322 |
| Popis: | Antibiotic use in neonates can have detrimental effects on the developing gut microbiome, increasing the risk of morbidity. A majority of preterm neonates receive antibiotics after birth without clear evidence to guide this practice. Here microbiome, metabolomic, and immune marker results from the routine early antibiotic use in symptomatic preterm Neonates (REASON) study are presented. The REASON study is the first trial to randomize symptomatic preterm neonates to receive or not receive antibiotics in the first 48 h after birth. Using 16S rRNA sequencing of stool samples collected longitudinally for 91 neonates, the effect of such antibiotic use on microbiome diversity is assessed. The results illustrate that type of nutrition shapes the early infant gut microbiome. By integrating data for the gut microbiome, stool metabolites, stool immune markers, and inferred metabolic pathways, an association was discovered between Veillonella and the neurotransmitter gamma-aminobutyric acid (GABA). These results suggest early antibiotic use may impact the gut-brain axis with the potential for consequences in early life development, a finding that needs to be validated in a larger cohort.Trial Registration This project is registered at clinicaltrials.gov under the name “Antibiotic ‘Dysbiosis’ in Preterm Infants” with trial number NCT02784821. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |